Esperer BioResearch urges Centre to introduce nutritional therapy in national cancer control programme for longer survival of patients

The Bengaluru-based Esperer BioResearch has urged the Union government to introduce a nutritional therapy programme in the national cancer control programme as it will enable a longer survival of patients with higher quality of life. The company's plea is based on the that globally oncologists have a rigorous nutritional evaluation for the early detected cancer patients to gauge their body’s ability to withstand toxicity of drugs.

The company now wanted the Indian oncologists also to ascertain the nutritional status of patients before they prescribe a cancer therapy. This is because malnourished patients are seen to increasingly succumb to the disease faster. The company has initiated talks with the Union government to adopt the nutritional therapy programme during its cancer detection programme and endorse its supplements.

The company’s six-year long research led to development of two products to combat nutritional deficiency in cancer patients. The first is Es-Fortitude which is formulated to nourish, protect and help recovery. The second is Es-In Vigour which is a base formula.

Globally, oncologists have a rigorous nutritional evaluation for the early detected cancer patients to gauge their body’s ability to withstand toxicity of drugs. In India, we have now asked the Union government to introduce a nutritional therapy programme in the national cancer control programme as it will enable a longer survival of patient with higher quality of life, said Raktim Chattopadhyay, Founder & CEO, Esperer BioResearch.

“We have also applied for patents from 19 countries. The product has gone through observatory studies, proof of concept and research was carried out at the Bio-Valley in Vizag and clinical trials are underway. However this is marketed in India after we received the FSSMP license to enable only prescription promotion,” he said adding, “The supplements provide optimal efficacy to main therapy in cancer disease management and can benefit approximately 2.25 million people living with cancer in India. However, it is the early detected cases that can benefit out of such focused nutritional supplements.”

Nutritional imbalance has a direct impact on the cancer disease. Our objective is to mitigate the risk that stems from nutritional deficiency. One of the most relevant syndromes that increases with cancer progression is cachexia that compromises the life of the patient and irremediably causes weakness and fatality. Hypermetabolism is correlated with clinical and biological markers of cancer cachexia and is associated with a shorter survival in metastatic cancer patients. Thus, there is a need for preparing the body for the treatment, during the treatment and during recovery stage. All three phases are different and require nutritional care on basis of the cell biology of the body, said Chattopadhyay.

The company is already researching on focused nutrition for breast and colorectal cancer. The products, for which 50 per cent ingredients are imported, are manufactured under contract at a US FDA approved nutraceutical plant in Bengaluru.

The marketing strategy is more hospital driven and hence it is available at HCG network of hospitals.

“Cancer encapsulates many different disease changes in metabolic pathways in cells. Therefore, no single metabolic therapy is right for a person. A scientific formula that can aid in maintaining the quality of life along with nutritional balance is a promising progress. We look forward to prescribing such effective health supplements and revolutionary formulas in the future,” said Dr. Radheshyam Naik, MD, HCG Hospital.

Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=116541&sid=1


Comments

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Tumour-targeting drug paves way for bone cancer treatment